Alto Neuroscience, Inc. (ANRO) - Q2 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2026. Alto Neuroscience is a clinical-stage biopharmaceutical company focused on developing personalized treatments for psychiatric disorders (MDD, TRD, BPD, schizophrenia, Parkinson's) using its Precision Psychiatry Platform. The company has no product revenue and relies on equity financings and debt to fund operations.
Key Financial Metrics
| Metric | Q2 2026 (3 Months) | YTD 2026 (6 Months) | YTD 2025 (6 Months) |
|---|---|---|---|
| Net Loss | $(27.6) million | $(53.9) million | $(32.9) million |
| Operating Expenses | $29.1 million | $56.3 million | $34.4 million |
| R&D Expenses | $22.1 million | $42.4 million | $23.1 million |
| G&A Expenses | $7.0 million | $13.9 million | $11.3 million |
| Cash & Equivalents (End of Period) | $243.7 million | $243.7 million | $176.5 million (Dec 31, 2025) |
| Net Cash Used in Operating Activities | N/A | $(46.9) million | $(30.3) million |
| Debt (Term Loan Principal) | $15.0 million | $15.0 million | $16.0 million (Dec 31, 2025) |
| Stock-Based Compensation | $3.6 million | $6.4 million | $4.0 million |
Material Changes vs. Prior Period
- Increased Burn Rate: Net loss for the six months ended June 30, 2026, increased by $21.0 million compared to the same period in 2025, driven primarily by higher R&D spending.
- R&D Expansion: R&D expenses rose $19.3 million YTD, largely due to the initiation of the Phase 2b trial for ALTO-207 (acquired from Chase Therapeutics) and continued development of ALTO-100, ALTO-300, and ALTO-101.
- Financing Activity: The company raised significant capital in the first half of 2026, including a March 2026 private placement yielding ~$114.8 million net proceeds. This offset the operating cash burn, resulting in a net increase in cash of $67.2 million for the six-month period.
- Debt Conversion: K2 HealthVentures LLC converted $1.0 million of the outstanding term loan into common stock in March 2026.
Outlook, Risks, and Unusual Items
- Subsequent Financing: On July 14, 2026 (post-period), the company completed an underwritten registered direct offering, raising approximately $94.6 million net proceeds.
- Liquidity: Management believes existing cash ($243.7M) plus the July 2026 proceeds and anticipated Wellcome Grant funds will support operations for at least the next 12 months.
- Clinical Milestones:
- ALTO-207: Phase 2b trial initiated in April 2026; Phase 3 readiness work expected by early 2027.
- ALTO-101: Phase 2 proof-of-concept for schizophrenia did not meet primary endpoints but showed directional improvements in EEG measures and favorable tolerability.
- ALTO-300 & ALTO-100: Phase 2b trials ongoing; topline data expected in 2027.
- Legal Proceedings: A putative securities class action regarding the 2024 IPO was filed in July 2025. The court granted the company's motion to dismiss in August 2026 but allowed the plaintiff to file a third amended complaint. No liability has been recorded.
- Debt Covenants: The company must maintain a cash runway of at least 5 months, unless market cap exceeds $700 million.
Investor Verification Checklist
- Cash Runway: Verify the updated cash runway calculation including the $94.6 million July 2026 proceeds against the current burn rate.
- ALTO-207 Trial Progress: Monitor enrollment rates and safety data for the newly initiated Phase 2b trial, which is the primary driver of current R&D spend.
- ALTO-101 Strategy: Assess management's plan for ALTO-101 following the mixed Phase 2 results (failed primary endpoints but positive secondary EEG signals).
- Dilution Impact: Review the impact of the March 2026 and July 2026 equity issuances on per-share ownership and future dilution from pre-funded warrants.
- Debt Obligations: Confirm compliance with the K2 HealthVentures loan covenants, specifically the 5-month cash runway requirement.